drugset / Trial / NCT07449390
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
Non-randomizedCrossoverOpen-labelOther
Summary
The primary objective of the trial is to assess the effect of multiple doses of the cytochrome P450 (CYP3A4) enzyme inducer carbamazepine (Part A) or the CYP3A4 inhibitor itraconazole (Part B) on the single-dose pharmacokinetics (PK) of AP31969 in healthy participants.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2026-05-09
- Completion
- 2026-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP31969 | Unknown | 350 mg | Oral |
| Subject | Carbamazepine | Small molecule | 300 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
Indications
No indication recorded.